Please wait...


Generic Name: edoxaban (e DOX a ban)
Brand Names: Savaysa
Savaysa (edoxaban) is used for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Includes Savaysa side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Savaysa

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Savaysa (edoxaban) blocks the activity of certain clotting substances in the blood. Savaysa is used to lower the risk of stroke caused by a blood clot in people with a heart rhythm disorder called atrial fibrillation. This medicine is used when the atrial fibrillation is not caused by a heart valve problem. Savaysa is also used to treat a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism). Savaysa should be used after 5 to 10 days of using an injectable blood thinner. Learn more

Savaysa Side Effects

Savaysa Side Effects

Note: This document contains side effect information about edoxaban. Some of the dosage forms listed on this page may not apply to the brand name Savaysa.

In Summary

More frequent side effects include: hemorrhage. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to edoxaban: oral tablet


Oral route (Tablet)

Edoxaban should not be used in patients with nonvalvular arterial fibrillation who have a CrCl greater than 95 mL/min due to an increased risk of ischemic stroke. Premature discontinuation of oral anticoagulant therapy may increase the risk of ischemic events. If edoxaban is discontinued for reasons other than pathological bleeding or therapy completion, consider covering with an alternative anticoagulant. Epidural or spinal hematomas, possibly resulting in permanent paralysis, may occur with edoxaban use during neuraxial anesthesia or spinal puncture. Consider the risk of edoxaban use in patients undergoing spinal procedures.

Along with its needed effects, edoxaban (the active ingredient contained in Savaysa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking edoxaban:

More common

  • Bloody nose
  • heavy non-menstrual vaginal bleeding
  • pale skin
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Less common

  • Bloody or black, tarry stools
  • vomiting of blood or material that looks like coffee grounds


  • Confusion
  • cough
  • difficulty with speaking
  • double vision
  • fever
  • headache, sudden, severe
  • inability to move the arms, legs, or facial muscles
  • inability to speak
  • nausea
  • slow speech
  • vomiting

Incidence not known

  • Back pain
  • bowel or bladder dysfunction
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • leg weakness
  • paralysis

Some side effects of edoxaban may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Rash

For Healthcare Professionals

Applies to edoxaban: oral tablet


During nonvalvular atrial fibrillation treatment, the most common adverse reactions were bleeding and anemia. During deep venous thromboembolism and pulmonary embolism treatment, the most common adverse reactions were bleeding, rash, abnormal liver function tests, and anemia.


Very common (10% or more): Any bleeding (21.7%), clinically-relevant non-major bleeding (up to 18.1%)

Common (1% to 10%): Major bleeding, anemia-related adverse events, non-fatal non-critical organ bleeding, clinically relevant bleeding, anemia

Uncommon (0.1% to 1%): Fatal bleeding, non-fatal critical organ bleeding, a 2 g/dL or greater decrease in hemoglobin, blood loss requiring transfusion of 2 or more units of RBC

Rare (less than 0.1%): Fatal non-intracranial bleeding

Major bleeding included intracranial hemorrhage (ICH), gastrointestinal hemorrhage, and fatal bleeds. A major bleeding event was defined as clinically overt bleeding that met one of the following criteria: fatal bleeding, symptomatic bleeding in a critical site (e.g. spine, eye), drop in hemoglobin of at least 2 g/dL, or a drop in hematocrit of at least 6%. A clinically relevant non-major bleed was defined as overt bleeding that required medical intervention.


Major GI bleeds included both upper and lower GI bleeds. A GUSTO severe GI bleed is defined as a severe or life-threatening bleed that causes hemodynamic compromise and requires intervention.

Common (1% to 10%): Major gastrointestinal (GI) bleeding, upper GI bleeding, lower GI bleeding (including anorectal bleeding), oral and pharyngeal bleeding

Uncommon (0.1% to 1%): GUSTO severe GI bleeding

Rare (less than 0.1%): Fatal GI bleed

Nervous system

ICH included hemorrhagic stroke, subarachnoid hemorrhage, epidural/subdural hemorrhage, and ischemic stroke with major hemorrhage.

Uncommon (0.1% to 1%): Any intracranial hemorrhage (ICH), hemorrhagic stroke, ICH other than hemorrhagic stroke, fatal ICH


Common (1% to 10%): Cutaneous soft tissue bleeding, rash


Common (1% to 10%): Vaginal bleeding, macroscopic hematuria, urethral bleeding


Common (1% to 10%): Abnormal liver function tests


Common (1% to 10%): Puncture site bleeding


Common (1% to 10%): Epistaxis

Uncommon (0.1% to 1%): Interstitial lung disease (ILD)

Most cases of ILD were confounded by concurrent amiodarone, which is known to cause ILD, or infectious pneumonia. Overall, 5 patients out of 5417 died of ILD during the course of the study.

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Savaysa